Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02462928
Registration number
NCT02462928
Ethics application status
Date submitted
2/06/2015
Date registered
4/06/2015
Date last updated
28/07/2020
Titles & IDs
Public title
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Query!
Scientific title
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)
Query!
Secondary ID [1]
0
0
2014-004579-22
Query!
Secondary ID [2]
0
0
150998-005
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CEDAR
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Macular Degeneration
0
0
Query!
Condition category
Condition code
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Abicipar Pegol
Treatment: Drugs - Ranibizumab
Other interventions - Sham Procedure
Experimental: Abicipar Pegol 2 mg (2Q8) - Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
Experimental: Abicipar Pegol 2 mg (2Q12) - Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
Active Comparator: Ranibizumab 0.5 mg (rQ4) - Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.
Treatment: Drugs: Abicipar Pegol
Abicipar pegol intravitreal injection.
Treatment: Drugs: Ranibizumab
Ranibizumab intravitreal injection.
Other interventions: Sham Procedure
Sham injection.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Stable Vision at Week 52
Query!
Assessment method [1]
0
0
Stable vision was defined as a loss of fewer than 15 letters in BCVA compared to baseline. BCVA was measured using an eye chart and reported as the number of letters read correctly using the Early Treatment of Diabetic Retinopathy Study (ETDRS) Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA loss of fewer than 15 letters are reported. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye.
Query!
Timepoint [1]
0
0
Baseline to Week 52
Query!
Secondary outcome [1]
0
0
Mean Change From Baseline in BCVA in the Study Eye at Week 52
Query!
Assessment method [1]
0
0
BCVA was measured using an eye chart and was reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their nondominant eye for treatment, or else the right eye was selected as the study eye. Mixed model for repeated measures (MMRM) analysis was used.
Query!
Timepoint [1]
0
0
Baseline to Week 52
Query!
Secondary outcome [2]
0
0
Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 52
Query!
Assessment method [2]
0
0
CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye. MMRM analysis was used.
Query!
Timepoint [2]
0
0
Baseline to Week 52
Query!
Secondary outcome [3]
0
0
Percentage of Participants With a Gain of 15 or More ETDRS Letters in BCVA From Baseline in Study Eye at Week 52
Query!
Assessment method [3]
0
0
BCVA was measured using an eye chart and reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye.
Query!
Timepoint [3]
0
0
Baseline to Week 52
Query!
Secondary outcome [4]
0
0
Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score in Study Eye at Week 52
Query!
Assessment method [4]
0
0
NEI-VFQ-25 consists of 25 vision-targeted questions that represent 11 vision-related quality of life subscales and one general health item. Responses of individual participants were recorded as scores that ranged between 0 (worst) to 100 (best vision related function) with higher scale indicating better vision related function. The overall composite score is then calculated by averaging over all 11 vision-targeted subscale scores, excluding the general health score. Overall composite score was calculated based on mean of non-missing subscales. Study eye was defined as eye that meets entry criteria. If both eyes met all of entry criteria, eye with worse BCVA at baseline (day 1) was selected. If BCVA values for both eyes were identical then participant had to select non-dominant eye, or else right eye was selected as study eye. A positive change from baseline indicates improvement. MMRM analysis was used.
Query!
Timepoint [4]
0
0
Baseline to Week 52
Query!
Eligibility
Key inclusion criteria
- Diagnosis of age-related macular degeneration in at least 1 eye
- Best corrected visual acuity of 20/40 to 20/320 in the study eye
- Best corrected visual acuity of 20/200 or better in the non-study eye
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of vitrectomy, macular surgery, or glaucoma surgery in the study eye
- Cataract or refractive surgery in the study eye within the last 3 months
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/06/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
19/06/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
939
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Hawaii
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Minnesota
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nevada
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Jersey
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New York
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Pennsylvania
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
South Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Utah
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Virginia
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Buenos Aires
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Santa Fe
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Cordoba
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Mendoza
Query!
Country [28]
0
0
Austria
Query!
State/province [28]
0
0
Graz
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Innsbruck
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Linz
Query!
Country [31]
0
0
Chile
Query!
State/province [31]
0
0
Las Condes
Query!
Country [32]
0
0
Chile
Query!
State/province [32]
0
0
Región Metropolitana
Query!
Country [33]
0
0
Colombia
Query!
State/province [33]
0
0
Valle Del Cauca
Query!
Country [34]
0
0
Colombia
Query!
State/province [34]
0
0
Bogota
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Brno
Query!
Country [36]
0
0
Czechia
Query!
State/province [36]
0
0
Olomouc
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Praha
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Bordeaux
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Creteil
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Lyon cedex 04
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Nantes Cedex 1
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Paris
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Saint Cyr sur Loire
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Bad Godesberg
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Dresden
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Dusseldorf
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Freiburg
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Gottingen
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Karlsruhe
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Leipzig
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Marburg
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Neubrandenburg
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Regensburg
Query!
Country [54]
0
0
Hong Kong
Query!
State/province [54]
0
0
Aberdeen
Query!
Country [55]
0
0
Hong Kong
Query!
State/province [55]
0
0
Kowloon
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Haifa
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Holon
Query!
Country [58]
0
0
Israel
Query!
State/province [58]
0
0
Kfar-Saba
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Petach Tikva
Query!
Country [60]
0
0
Israel
Query!
State/province [60]
0
0
Rehovot
Query!
Country [61]
0
0
Israel
Query!
State/province [61]
0
0
Tel Aviv
Query!
Country [62]
0
0
Israel
Query!
State/province [62]
0
0
Tel Hashomer
Query!
Country [63]
0
0
Israel
Query!
State/province [63]
0
0
Zerifin
Query!
Country [64]
0
0
Korea, Republic of
Query!
State/province [64]
0
0
Gyeonggi-do
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Seoul
Query!
Country [66]
0
0
Latvia
Query!
State/province [66]
0
0
LV
Query!
Country [67]
0
0
New Zealand
Query!
State/province [67]
0
0
Auckland
Query!
Country [68]
0
0
Philippines
Query!
State/province [68]
0
0
Metro Manila
Query!
Country [69]
0
0
Singapore
Query!
State/province [69]
0
0
Singapore
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Barcelona
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Bilbao
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Madrid
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Pamplona
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Valencia
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Valladolid
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Zaragoza
Query!
Country [77]
0
0
Switzerland
Query!
State/province [77]
0
0
Bern
Query!
Country [78]
0
0
Switzerland
Query!
State/province [78]
0
0
Binningen
Query!
Country [79]
0
0
Switzerland
Query!
State/province [79]
0
0
Zurich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Allergan
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a safety and efficacy study of abicipar pegol in participants with neovascular
age-related macular degeneration.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02462928
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Joanne Li
Query!
Address
0
0
Allergan
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02462928
Download to PDF